Bailard’s Y-mAbs Therapeutics YMAB Stock Holding History

Bailard’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,900	Closed	-$115K	–	829
2023 Q4	$115K	Buy	+16,900	New	+$97.7K	﹤0.01%	681

Other funds holding YMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bailard's YMAB Position: Q1 2024 in Review

Bailard sold out of Y-mAbs Therapeutics (YMAB) in Q1 2024, closing a stake of 16,900 shares — an estimated $115K sold.

Bailard first reported a position in YMAB in Q4 2023 and held it in 1 quarter. The position peaked at $115K in Q4 2023. 96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

Bailard reported no remaining Y-mAbs Therapeutics position as of Q1 2024 after selling out during the quarter.
Bailard sold 16,900 Y-mAbs Therapeutics shares in Q1 2024, an estimated $115K.
Bailard first reported a position in Y-mAbs Therapeutics in Q4 2023 and held it in 1 quarter.
Bailard's Y-mAbs Therapeutics position peaked at $115K in Q4 2023.
96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on Bailard's 13F filing for Q1 2024, filed 8 May 2024.